News

Call for Judges for Science Fair and BioGENEius Challenge

Each year, Virginia Bio recruits volunteer judges from the membership to attend the Virginia State Science and Engineering Fair to select the top three winners in the field of biosciences. This year’s fair will be held virtually on April 10, 2021, hosted virtually by the Virginia Tech Carilion School of Medicine in Roanoke’s Berglund Special Events Center. Judges will be sent applicant information, abstracts and posters to review.

Volunteer judges are also needed for the Virginia BioGENEius Challenge. Students submit their projects in either the categories of biotechnology, agriculture or industrial/ environmental science. The judging for the challenge is done virtually. Judges will be sent applicant information, abstracts and posters by May 10, and results will be due back to Virginia Bio on May 19. Winners from the state challenge will go on to compete in the U.S. National BioGENEius Challenge taking place during the BIO International Conference in June.

Please contact Caron Trumbo if interested in volunteering your time!

Recent News

06/29/2022

Bio-plastics startup wins Lighthouse Labs pitch contest

Charlottsville, VA (Virginia Business) – While pitching to the sharks, entrepreneur Alec Brewer told them, “I do have white powder in my pocket,” before quickly clarifying that it wasn’t an illicit substance: “It’s PHB! It’s PHB!” The co-founder and CEO of Charlottesville-based biodegradable plastics manufacturer Ourobio, Brewer explained that his company makes PHB, or polyhydroxybutyrate,

06/26/2022

USA FDA Grants Fast Track Designation to ReAlta Life Sciences’ Lead Compound RLS-0071

ReAlta Life Sciences (“ReAlta”), Inc., a clinical stage, rare disease company dedicated to harnessing the power of the immune system to address life threatening diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to RLS-0071 for the treatment of hypoxic ischemic encephalopathy (HIE). RLS-0071 is the Company’s lead dual

06/20/2022

Adial Pharmaceuticals Awarded Additional U.S. Patent Combining the Use of the Company’s Proprietary Genetic Diagnostic With AD04 to Treat Alcohol and Drug Dependence

New patent covers the use of the full genetic panel measuring all five genetic biomarkers CHARLOTTESVILLE, Va., — Adial Pharmaceuticals, Inc. (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11,351,154 was issued on June 7, 2022, by